نتایج جستجو برای: mdm2 snp309

تعداد نتایج: 4579  

ژورنال: :مجله دانشگاه علوم پزشکی شهید صدوقی یزد 0
محمد علی حسین پور فیضی m hossein pour feizi صغری تقی زاده s taghizadeh ناصر پولادی n pouladi پروین آذرفام p azarfam وحید منتظری v montazeri

مقدمه: آنکوژن mdm2فسفوپروتئینی با خاصیت یوبیکوئیتین لیگازی کد می کند که باعث ممانعت از فعالیتp53 و پیش برندگی تخریب آن می شود. اخیرا یک جانشینی t به g در پروموتر ژن mdm2(snp309)، شناسایی شده و ارتباط آن با بیان افزایش یافته mdm2 نشان داده شده است و مشخص گردیده که این بیان افزایش یافته با بروز در سنین پایین چندین تومور از جمله سرطان سینه همراه است. از این رو شاید بتوان آن را به عنوان یک مارکر اس...

2011
Moriko Ito Louise Barys Terence O’Reilly Sophie Young Bella Gorbatcheva John Monahan Sabine Zumstein-Mecker Peter F. Choong Ian Dickinson Philip Crowe Christine Hemmings Jayesh Desai David M. Thomas Joanna Lisztwan

Purpose: Reactivation of p53 tumor suppressor activity in diseases such as soft-tissue sarcoma is considered an attractive means of targeted therapy. By systematically assessing alterations affecting the p53 pathway, we aimed to (a) classify sarcoma subtypes, (b) define a potential role in malignancy, and (c) identify potential patient biomarkers in this heterogeneous disease. Experimental Desi...

Journal: :Blood 2013
Zijun Y Xu-Monette Michael B Møller Alexander Tzankov Santiago Montes-Moreno Wenwei Hu Ganiraju C Manyam Louise Kristensen Lei Fan Carlo Visco Karen Dybkaer April Chiu Wayne Tam Youli Zu Govind Bhagat Kristy L Richards Eric D Hsi William W L Choi J Han van Krieken Qin Huang Jooryung Huh Weiyun Ai Maurilio Ponzoni Andrés J M Ferreri Lin Wu Xiaoying Zhao Carlos E Bueso-Ramos Sa A Wang Ronald S Go Yong Li Jane N Winter Miguel A Piris L Jeffrey Medeiros Ken H Young

MDM2 is a key negative regulator of the tumor suppressor p53, however, the prognostic significance of MDM2 overexpression in diffuse large B-cell lymphoma (DLBCL) has not been defined convincingly. In a p53 genetically-defined large cohort of de novo DLBCL patients treated with rituximab, cyclophosphamide, hydroxydaunorubicin, vincristine, and prednisone (R-CHOP) chemotherapy, we assessed MDM2 ...

2017
Alexandra J van den Broek Annegien Broeks Hugo M Horlings Sander VM Canisius Linde M Braaf Anita Langerød Laura J Van ’t Veer Marjanka K Schmidt

assoCIatIon of the GermlIne MDM2 snp309 and TP53 r72p varIants WIth breast CanCer survival in sPeciFic tumor subgrouPs. absTRacT The tumor suppressor gene TP53 and its regulator MDM2 are both important players in the DNA-damage repair 'TP53 response pathway'. Common germline polymorphisms in these genes may affect outcome in patients with tumors characterized by additional somatic changes in th...

2010
Shenying Fang Ralf Krahe Guillermina Lozano Younghun Han Wei Chen Sean M. Post Baili Zhang Charmaine D. Wilson Linda L. Bachinski Louise C. Strong Christopher I. Amos

BACKGROUND Previous studies have shown that MDM2 SNP309 and p53 codon 72 have modifier effects on germline P53 mutations, but those studies relied on case-only studies with small sample sizes. The impact of MDM4 polymorphism on tumor onset in germline mutation carriers has not previously been studied. METHODOLOGY/PRINCIPAL FINDINGS We analyzed 213 p53 germline mutation carriers including 168(...

Journal: :The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases 2014
Ludmila Gonçalves Entiauspe Fabiana Kömmling Seixas Emily Montosa Nunes Fernanda Martins Rodrigues Odir A Dellagostin Tiago Collares Mariângela Freitas da Silveira

BACKGROUND It is believed that Human Papillomavirus (HPV) and Human Immunodeficiency Virus coinfection contributes to increase the risk for cervical intraepithelial injuries. Several factors may contribute to cervical cancer (CC) development, including genetic variants such as TP53 and MDM2 gene polymorphisms. MATERIALS AND METHODS A hundred HIV-infected women were examined for HPV detection ...

Journal: :Cancer research 2006
Gareth L Bond Kim M Hirshfield Tomas Kirchhoff Gabriella Alexe Elisabeth E Bond Harlan Robins Frank Bartel Helge Taubert Peter Wuerl William Hait Deborah Toppmeyer Kenneth Offit Arnold J Levine

The importance of the p53 stress response pathway in the suppression of tumor formation is well documented. In a previous report, a single nucleotide polymorphism (SNP309 T/G) was found in the promoter of the MDM2 gene resulting in higher levels of MDM2 RNA and protein and, consequently, in the attenuation of the p53 pathway both in vitro and in vivo. As the SNP309 locus is found in a region of...

Journal: :Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2007
Zhibin Hu Guangfu Jin Lu Wang Feng Chen Xinru Wang Hongbing Shen

Since the identification of a well-characterized functional polymorphism named SNP309 in MDM2, abundant studies were published in the last 2 years to evaluate the association between SNP309 and tumor risk in diverse populations. However, the results remain conflicting rather than conclusive. Because a single study may have been underpowered to detect the effect of low-penetrance genes, a quanti...

Journal: :Oncology reports 2008
Yohei Horikawa Junichi Nadaoka Mitsuru Saito Teruaki Kumazawa Takamitu Inoue Takeshi Yuasa Norihiko Tsuchiya Hiroyuki Nishiyama Osamu Ogawa Tomonori Habuchi

Recent studies have shown that functional polymorphisms at the MDM2 SNP309 T/G and p53 Arg72Pro may be associated with cancer susceptibility. However, the role of these polymorphisms on the risk of transitional cell carcinoma of the bladder (TCCB) and clinical outcome remains unknown. SNP309 and p53 Arg72Pro polymorphisms were genotyped in 227 patients and 266 control subjects. The association ...

2017
Christophe Deben Ken Op de Beeck Jolien Van den Bossche Julie Jacobs Filip Lardon An Wouters Marc Peeters Guy Van Camp Christian Rolfo Vanessa Deschoolmeester Patrick Pauwels

Objectives: Two functional polymorphisms in the MDM2 promoter region, SNP309T>G and SNP285G>C, have been shown to impact MDM2 expression and cancer risk. Currently available data on the prognostic value of MDM2 SNP309 in non-small cell lung cancer (NSCLC) is contradictory and unavailable for SNP285. The goal of this study was to clarify the role of these MDM2 SNPs in the outcome of NSCLC patien...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید